Incyte causes stir with experimental drug data

Incyte made a stir at JP Morgan with positive early-stage results for its experimental drugs aimed at rheumatoid arthritis and diabetes. Its shares jumped about 25 percent on the news. Chief Executive Dr. Paul Friedman said early data from INCB18424 appear to show "at least equal, and possibly superior," results compared to other biologics, adding that the drug was well tolerated.

- read the release

Related Articles:
Focus shifts at Incyte after HIV halt. Report
Pfizer to pay up to $803M for rights to Incyte program. Report
Incyte shares drop after FDA requires new Phase II. Report